NCT03013491 2025-06-17PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasCytomX TherapeuticsPhase 1/2 Terminated196 enrolled 28 charts
NCT01986426 2018-10-03LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabLytix Biopharma ASPhase 1 Completed80 enrolled
NCT00060372 2013-03-27Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNational Cancer Institute (NCI)Phase 1 Completed21 enrolled